Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cartesian Therapeutics ( (RNAC) ) has provided an announcement.
On October 15, 2025, Cartesian Therapeutics, Inc. announced the elimination of the Chief Scientific Officer position, leading to the termination of Christopher Jewell, Ph.D., effective November 14, 2025. The company and Dr. Jewell entered into a separation agreement on October 20, 2025, which includes severance payments and benefits in exchange for releasing any claims against the company, reflecting a strategic shift in the company’s operations.
The most recent analyst rating on (RNAC) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.
Spark’s Take on RNAC Stock
According to Spark, TipRanks’ AI Analyst, RNAC is a Underperform.
The overall stock score is heavily influenced by the company’s poor financial performance and weak valuation metrics. The technical analysis also indicates bearish trends, further contributing to the low score. The absence of earnings call insights or notable corporate events leaves these negative factors unmitigated.
To see Spark’s full report on RNAC stock, click here.
More about Cartesian Therapeutics
Average Trading Volume: 67,071
Technical Sentiment Signal: Sell
Current Market Cap: $253.5M
For an in-depth examination of RNAC stock, go to TipRanks’ Overview page.